CF PharmTech raises HK$300.5M in H share placement, months after IPO
What's the deal? CF PharmTech, a commercial-stage pharmaceutical company focused on inhalation drug delivery, is raising HK$300.55 million ($38.3 million) through a placement of 21,747,700 new H shares. The shares are priced at HK$13.82 each — an 11.97% discount to the last close — with net proceeds of about HK$294.81 million.
Why now? The placement comes just months after the company's October 2025 global offering, which it says remains largely unutilised and reserved for previously disclosed purposes. It uses an existing general mandate, so no further shareholder approval is required, and completion is targeted for August 6, 2026.
What's the endgame? CF PharmTech is positioning itself as a global inhalation drug delivery platform. It will direct 70% of proceeds to clinical and pre-clinical development of innovative drug candidates, including trials for idiopathic pulmonary fibrosis and pulmonary hypertension. Another 15% goes to complex inhalation formulation products and 15% to working capital.
What could go wrong? The raise dilutes existing holders, representing 5.30% of total shares pre-placement. The discount, dilution, and a 90-day lock-up on further issuance are all flagged as potentially price-sensitive.
The shares will be placed with at least six independent investors, lifting the public float from 56.7% to 58.9%. Total issued shares rise from 411,978,387 to 433,726,087, and the company says it remains compliant with minimum public float rules.
The signal: A quick re-raise so soon after listing signals a capital-hungry pipeline. For a clinical-stage drug developer, tapping public markets under an existing mandate is a fast route to fund trials — but leaning on it while prior IPO funds sit largely unspent invites scrutiny.
Read more: minichart.com.sg
